順天堂大学医学部附属浦安病院は、千葉県浦安市富岡2-1-1にある病院であり、学校法人順天堂が運営する大学付属病院である。

During the past decade, Juntendo University Urayasu Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Juntendo University Urayasu Hospital" #1 sponsor was "Haruhiko Fukuda" with 3 trials, followed by "Chugai Pharmaceutical" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Juntendo University" with 2 trials sponsored and "Allergan" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Juntendo University Urayasu Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 3 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Japan Blood Products Organization" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Juntendo University Urayasu Hospital" are "Psoriasis" (2 trials), "Acute Heart Failure" (1 trials), "Arrhythmias, Cardiac" (1 trials), "Colorectal Cancer" (1 trials) and "Colorectal Neoplasms" (1 trials). Many other conditions were trialed in "Juntendo University Urayasu Hospital" in a lesser frequency.

Most popular intervention types in "Juntendo University Urayasu Hospital" are "Drug" (9 trials), "Device" (2 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Mirikizumab" (2 trials), "5FU+l-leucovorin" (1 trials), "Abicipar Pegol" (1 trials) and "Antithrombin gamma" (1 trials). Other intervention names were less common.

The vast majority of trials in "Juntendo University Urayasu Hospital" are 14 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Juntendo University Urayasu Hospital". undefined are not yet recruiting, 6 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Juntendo University Urayasu Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Juntendo University Urayasu Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".